EP2560656A4 - Antivirale verbindungen - Google Patents

Antivirale verbindungen

Info

Publication number: EP2560656A4
Authority: EP; European Patent Office
Prior art keywords: antiviral compounds; antiviral; compounds
Prior art date: 2010-04-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP11772675.2A

Other languages

English (en)

French (fr)

Other versions

EP2560656A2 (de

Inventor

Shawn P Iadonato

Kristin Bedard

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kineta Inc

Original Assignee

Kineta Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-23

Filing date

2011-04-20

Publication date

2013-11-27

2011-04-20 Application filed by Kineta Inc filed Critical Kineta Inc

2013-02-27 Publication of EP2560656A2 publication Critical patent/EP2560656A2/de

2013-11-27 Publication of EP2560656A4 publication Critical patent/EP2560656A4/de

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP11772675.2A 2010-04-23 2011-04-20 Antivirale verbindungen Withdrawn EP2560656A4 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32756610P	2010-04-23	2010-04-23
PCT/US2011/033326 WO2011133722A2 (en)	2010-04-23	2011-04-20	Anti-viral compounds

Publications (2)

Publication Number	Publication Date
EP2560656A2 EP2560656A2 (de)	2013-02-27
EP2560656A4 true EP2560656A4 (de)	2013-11-27

Family

ID=44834797

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11772675.2A Withdrawn EP2560656A4 (de)	2010-04-23	2011-04-20	Antivirale verbindungen

Country Status (12)

Country	Link
US (1)	US8927561B2 (de)
EP (1)	EP2560656A4 (de)
JP (1)	JP2013525366A (de)
KR (1)	KR20130069640A (de)
CN (1)	CN102939088A (de)
AU (1)	AU2011242683A1 (de)
BR (1)	BR112012026641A2 (de)
CA (1)	CA2812043A1 (de)
IL (1)	IL222634A0 (de)
MX (1)	MX2012012353A (de)
TW (1)	TW201202244A (de)
WO (1)	WO2011133722A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2010007419A (es)	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2799579A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ES2637113T3 (es)	2011-01-10	2017-10-10	Infinity Pharmaceuticals, Inc.	Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
AR088218A1 (es)	2011-07-19	2014-05-21	Infinity Pharmaceuticals Inc	Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es)	2011-08-29	2014-07-09	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
CN103842364A (zh) *	2011-09-30	2014-06-04	奇尼塔公司	抗病毒化合物
RS58514B1 (sr)	2012-06-13	2019-04-30	Incyte Holdings Corp	Supstituisana triciklična jedinjenja kao inhibitori fgfr
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG11201506924YA (en)	2013-03-15	2015-09-29	Incyte Corp	Tricyclic heterocycles as bet protein inhibitors
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
DK3013813T3 (da)	2013-06-27	2019-06-03	Pfizer	Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
EP3019502B1 (de)	2013-07-08	2017-05-17	Incyte Holdings Corporation	Tricyclische heterocyclen als bet-proteininhibitoren
WO2015077572A1 (en)	2013-11-22	2015-05-28	CL BioSciences LLC	Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
WO2015081189A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en)	2013-11-26	2016-07-26	Incyte Corporation	Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
CN103695543B (zh) *	2013-12-16	2016-04-06	中国人民解放军第二军医大学	模式识别受体rig-i在制备肿瘤诊断或预后评估试剂盒中的应用
WO2015095492A1 (en)	2013-12-19	2015-06-25	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
PL3134403T3 (pl)	2014-04-23	2020-07-13	Incyte Corporation	1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
JP6599979B2 (ja)	2014-09-15	2019-10-30	インサイト・コーポレイション	Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh)	2015-02-20	2020-12-11	美商英塞特公司	作為fgfr抑制劑之雙環雜環
WO2017075377A1 (en)	2015-10-29	2017-05-04	Incyte Corporation	Amorphous solid form of a bet protein inhibitor
PT3442972T (pt)	2016-04-15	2020-05-29	Abbvie Inc	Inibidores de bromodomínio
CA3028689A1 (en)	2016-06-20	2017-12-28	Incyte Corporation	Crystalline solid forms of a bet inhibitor
SG11201811237WA (en)	2016-06-24	2019-01-30	Infinity Pharmaceuticals Inc	Combination therapies
JOP20190024A1 (ar)	2016-08-26	2019-02-19	Gilead Sciences Inc	مركبات بيروليزين بها استبدال واستخداماتها
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7050165B2 (ja)	2018-02-26	2022-04-07	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
HRP20241288T1 (hr)	2018-05-04	2024-12-06	Incyte Corporation	Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en)	2018-05-04	2024-09-12	Incyte Corporation	Salts of an FGFR inhibitor
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en)	2019-10-14	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja)	2019-12-04	2026-03-18	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000061563A1 (en) *	1999-04-10	2000-10-19	Samjin Pharmaceutical Co., Ltd.	Antiviral pyrimidinedione derivatives and process for the preparation thereof
WO2008107436A1 (en) *	2007-03-06	2008-09-12	Novartis Ag	Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
WO2008109180A2 (en) *	2007-03-07	2008-09-12	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors containing a heterocyclic moiety
WO2008147962A1 (en) *	2007-05-23	2008-12-04	Siga Technologies, Inc.	Antiviral drugs for treatment or prevention of dengue infection
US20090163545A1 (en) *	2007-12-21	2009-06-25	University Of Rochester	Method For Altering The Lifespan Of Eukaryotic Organisms

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7947691B2 (en) *	2004-07-21	2011-05-24	Athersys, Inc.	Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof

2011
- 2011-04-20 KR KR1020127030543A patent/KR20130069640A/ko not_active Withdrawn
- 2011-04-20 BR BR112012026641A patent/BR112012026641A2/pt not_active IP Right Cessation
- 2011-04-20 US US13/642,818 patent/US8927561B2/en not_active Expired - Fee Related
- 2011-04-20 EP EP11772675.2A patent/EP2560656A4/de not_active Withdrawn
- 2011-04-20 WO PCT/US2011/033326 patent/WO2011133722A2/en not_active Ceased
- 2011-04-20 JP JP2013506286A patent/JP2013525366A/ja not_active Ceased
- 2011-04-20 AU AU2011242683A patent/AU2011242683A1/en not_active Abandoned
- 2011-04-20 MX MX2012012353A patent/MX2012012353A/es not_active Application Discontinuation
- 2011-04-20 CA CA2812043A patent/CA2812043A1/en not_active Abandoned
- 2011-04-20 CN CN2011800293435A patent/CN102939088A/zh active Pending
- 2011-04-22 TW TW100114196A patent/TW201202244A/zh unknown
2012
- 2012-10-23 IL IL222634A patent/IL222634A0/en unknown

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000061563A1 (en) *	1999-04-10	2000-10-19	Samjin Pharmaceutical Co., Ltd.	Antiviral pyrimidinedione derivatives and process for the preparation thereof
WO2008107436A1 (en) *	2007-03-06	2008-09-12	Novartis Ag	Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
WO2008109180A2 (en) *	2007-03-07	2008-09-12	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors containing a heterocyclic moiety
WO2008147962A1 (en) *	2007-05-23	2008-12-04	Siga Technologies, Inc.	Antiviral drugs for treatment or prevention of dengue infection
US20090163545A1 (en) *	2007-12-21	2009-06-25	University Of Rochester	Method For Altering The Lifespan Of Eukaryotic Organisms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEDARD K ET AL: "Small Molecule Agonists of the RIG-I Pathway and their Potent Antiviral Actions", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 86, no. 1, 1 April 2010 (2010-04-01), pages A25, XP027018255, ISSN: 0166-3542, [retrieved on 20100401] *
R. SUMPTER ET AL: "Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis C Virus RNA Replication through a Cellular RNA Helicase, RIG-I", JOURNAL OF VIROLOGY, vol. 79, no. 5, 11 February 2005 (2005-02-11), pages 2689 - 2699, XP055067887, ISSN: 0022-538X, DOI: 10.1128/JVI.79.5.2689-2699.2005 *

Also Published As

Publication number	Publication date
BR112012026641A2 (pt)	2016-07-12
KR20130069640A (ko)	2013-06-26
EP2560656A2 (de)	2013-02-27
IL222634A0 (en)	2012-12-31
MX2012012353A (es)	2013-02-07
WO2011133722A3 (en)	2012-04-05
AU2011242683A1 (en)	2012-12-13
US20130045229A1 (en)	2013-02-21
TW201202244A (en)	2012-01-16
CN102939088A (zh)	2013-02-20
WO2011133722A2 (en)	2011-10-27
US8927561B2 (en)	2015-01-06
JP2013525366A (ja)	2013-06-20
CA2812043A1 (en)	2011-10-27

Legal Events

Date	Code	Title	Description
2013-01-25	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-02-27	17P	Request for examination filed	Effective date: 20121121
2013-02-27	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-07-31	DAX	Request for extension of the european patent (deleted)
2013-11-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1182007 Country of ref document: HK
2013-11-27	A4	Supplementary search report drawn up and despatched	Effective date: 20131030
2013-11-27	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/495 20060101ALI20131024BHEP Ipc: A61P 31/12 20060101ALI20131024BHEP Ipc: A61K 31/519 20060101AFI20131024BHEP Ipc: C07D 487/04 20060101ALI20131024BHEP
2016-06-08	17Q	First examination report despatched	Effective date: 20160512
2017-01-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2017-02-22	18D	Application deemed to be withdrawn	Effective date: 20160923
2019-11-29	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1182007 Country of ref document: HK

Publication	Publication Date	Title
EP2560656A4 (de)	2013-11-27	Antivirale verbindungen
EP2560652A4 (de)	2013-08-14	Antivirale verbindungen
EP2560636A4 (de)	2013-11-27	Antivirale verbindungen
EP2590647A4 (de)	2014-05-21	Pro-neurogene verbindungen
SMT201600351B (it)	2016-11-10	Composti antivirali
EP2648516A4 (de)	2014-04-30	Substituierte pyridinon-pyridinyl-verbindungen
CR20130231A (es)	2013-09-19	Compuestos antivirales
BR112014007781A2 (pt)	2017-04-11	compostos anti-virais
EP2605658A4 (de)	2014-05-07	Spiroxazolidinonverbindungen
EP2925129A4 (de)	2016-06-08	Pro-neurogene verbindungen
MA35423B1 (fr)	2014-09-01	Composés de cyclopropanamine
EP2887803A4 (de)	2016-08-03	Pro-neurogene verbindungen
BR112013009935C8 (pt)	2017-09-19	compostos
EP2673286A4 (de)	2015-01-21	Therapeutische verbindungen
PL2614063T3 (pl)	2016-06-30	Podstawione imidazopirydazyny
EP2519525A4 (de)	2013-06-12	Substituierte pyrrolo-aminopyrimidin-verbindungen
JP2013525366A5 (ja)	2014-06-05	ピリミジンジオン抗ウイルス性化合物
EP2927231A4 (de)	2016-04-20	Imidazopyridinverbindung
DOP2012000224A (es)	2013-01-31	Compuesto heterociclico
JP2013525368A5 (ja)	2014-06-05	スルホンアミド抗ウイルス性化合物
CO6801726A2 (es)	2013-11-29	Compuestos
EP2920181A4 (de)	2016-07-27	Pyrazolopyrimidinverbindungen
EP2560657A4 (de)	2014-02-19	Antivirale verbindungen
EP2616453A4 (de)	2014-07-02	Antimetastasen-verbindungen
EP2555766A4 (de)	2015-06-03	Antimetastasen-verbindungen